Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of BAT4406F in minimal change disease or focal segmental glomerulosclerosis (Phase II only currently conducted)
CTR20253861Phase 3Active
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of BAT4406F in nephrosis, focal segmental glomerulosclerosis (FSGS), sponsored by Bio-Thera Solutions, Ltd.. Started Oct 2025; status: active.
02
Drugs
BAT4406F
03
Conditions
nephrosisfocal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on CTR20253861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253861.